Duration of short-course androgen suppression therapy and the risk of death as a result of prostate cancer.
Authors
D'Amico, Anthony VChen, Ming-Hui
Crook, Juanita
Armstrong, John G
Malone, Shawn
Steigler, Allison
Dunne, Mary
Kantoff, Philip W
Denham, James W
Affiliation
Brigham and Women's Hospital, Boston, MA 02115, USA. adamico@partners.orgIssue Date
2011-12-10MeSH
AgedAndrogen Antagonists
Antineoplastic Agents, Hormonal
Cohort Studies
Combined Modality Therapy
Humans
Male
Neoplasm Staging
Prognosis
Prostatic Neoplasms
Treatment Outcome
Metadata
Show full item recordCitation
Duration of short-course androgen suppression therapy and the risk of death as a result of prostate cancer. 2011, 29 (35):4682-7 J. Clin. Oncol.Journal
Journal of clinical oncology : official journal of the American Society of Clinical OncologyDOI
10.1200/JCO.2011.37.0726PubMed ID
22042952Abstract
We evaluated whether the duration of androgen suppression therapy (AST) had an impact on the risk of prostate cancer-specific mortality (PCSM) in men with unfavorable-risk prostate cancer (PC) within established Gleason score (GS) categories.Item Type
ArticleLanguage
enISSN
1527-7755ae974a485f413a2113503eed53cd6c53
10.1200/JCO.2011.37.0726
Scopus Count
Collections
Related articles
- Total androgen blockade versus a luteinizing hormone-releasing hormone agonist alone in men with high-risk prostate cancer treated with radiotherapy.
- Authors: Nanda A, Chen MH, Moran BJ, Braccioforte MH, Dosoretz D, Salenius S, Katin M, Ross R, D'Amico AV
- Issue date: 2010 Apr
- Greatest percentage of involved core length and the risk of death from prostate cancer in men with highest Gleason score ≥ 7.
- Authors: Cheney MD, Chen MH, Zhang D, Phillips JG, Loffredo MJ, D'Amico AV
- Issue date: 2014 Aug
- Duration of testosterone suppression and the risk of death from prostate cancer in men treated using radiation and 6 months of hormone therapy.
- Authors: D'Amico AV, Renshaw AA, Loffredo B, Chen MH
- Issue date: 2007 Oct 15
- Six-month androgen suppression plus radiation therapy compared with radiation therapy alone for men with prostate cancer and a rapidly increasing pretreatment prostate-specific antigen level.
- Authors: D'Amico AV, Loffredo M, Renshaw AA, Loffredo B, Chen MH
- Issue date: 2006 Sep 1
- Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial.
- Authors: Denham JW, Joseph D, Lamb DS, Spry NA, Duchesne G, Matthews J, Atkinson C, Tai KH, Christie D, Kenny L, Turner S, Gogna NK, Diamond T, Delahunt B, Oldmeadow C, Attia J, Steigler A
- Issue date: 2019 Feb